Nellix Endovascular
Stage
Acquired | AcquiredTotal Raised
$16.5MValuation
$0000About Nellix Endovascular
Nellix has developed a percutaneously deliverable endograft for the treatment of Abdominal Aortic Aneurysms and Thoracic Aortic Aneurysms. This aortic endograft device and treatment fills the aneurysm, providing a highly stable and durable seal. The technology aims to allow treatment of all aortic aneurysms and aims to provide a distinct advantage over current therapies.
Missing: Nellix Endovascular's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Nellix Endovascular's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Nellix Endovascular Patents
Nellix Endovascular has filed 21 patents.
The 3 most popular patent topics include:
- Vascular diseases
- Vascular surgery
- Diseases of the aorta
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/13/2018 | 2/2/2021 | Vascular diseases, Diseases of the aorta, Implants (medicine), Vascular surgery, Cardiac surgery | Grant |
Application Date | 7/13/2018 |
|---|---|
Grant Date | 2/2/2021 |
Title | |
Related Topics | Vascular diseases, Diseases of the aorta, Implants (medicine), Vascular surgery, Cardiac surgery |
Status | Grant |
Latest Nellix Endovascular News
May 12, 2020
News Endologix announces completion of enrollment in the EVAS2 Confirmatory Clinical Study to evaluate the Nellix EndoVascular Aneurysm Sealing System The Company is currently in the process of preparing a PMA submission, which it plans to submit shortly after the first 95 patients in the trial reach one-year follow-up in March 2021 Endologix completes enrolling patients for EVAS2 Confirmatory Clinical Study. Endologix, a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing (EVAS) System. “The completion of enrollment in our EVAS2 study is an exciting milestone for Endologix and for the treatment of abdominal aortic aneurysms,” commented John Onopchenko, Chief Executive Officer of Endologix. “We are very grateful for the ongoing collaboration and partnership with our investigators who continue to work side-by-side with us to make this trial successful.” In response to the current COVID-19 pandemic and the delay in recruiting patients across many clinical trials, Endologix submitted an IDE supplement to the FDA with a revised Statistical Analysis Plan that is consistent with the recently published FDA Guidance document, Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic. The submission proposed a minimum sample size of 95 patients, with no alteration to the defined end points of the study. The power of the two-year effectiveness endpoint has been reduced to 87.4% from 93.8%, and the power of the safety endpoint remains 99.9%. The statistical power of both end points remains well above the 80% benchmark typically used in this therapeutic area. The Company is currently in the process of preparing a PMA submission, which it plans to submit shortly after the first 95 patients in the trial reach one-year follow-up in March 2021. Source: Company Press Release
Nellix Endovascular Frequently Asked Questions (FAQ)
Where is Nellix Endovascular's headquarters?
Nellix Endovascular's headquarters is located at 2465-B Faber Place, Palo Alto.
What is Nellix Endovascular's latest funding round?
Nellix Endovascular's latest funding round is Acquired.
How much did Nellix Endovascular raise?
Nellix Endovascular raised a total of $16.5M.
Who are the investors of Nellix Endovascular?
Investors of Nellix Endovascular include Endologix, Incept, EW Healthcare Partners, Band of Angels, BioStar Capital and 4 more.
Who are Nellix Endovascular's competitors?
Competitors of Nellix Endovascular include Endologix, TriVascular, Aptus Endosystems, Micrus Endovascular, nFocus Neuromedical and 9 more.
Compare Nellix Endovascular to Competitors
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
Researcher and developer of a minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novocell.
Monteris Medical develops MRI-guided neurosurgical ablation tools and solutions for neurosurgeons. The company creates a system enabling surgeons to reach lesions that are difficult to access with standard surgery or were previously considered inoperable. Monteris offers 'The NeuroBlate System', a neurosurgical ablation device providing controlled therapy for brain lesions, the Monteris Mini-Bolt, a cranial bolt system that enables a robotic interface for protected and precise therapy delivery, as well as the AtamA Stabilization System for MRI-guided neurosurgical procedures requiring head fixation. It serves clients in the healthcare sector. The company was founded in 1999 and is based in Hopkins, Minnesota.
Gynesonics women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. It develops the Sonata System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata System uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. Gynesonics was founded in 2005 and is based in Redwood City, California.
Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.